Neuropharmacology of Alcohol, Opioids, and Cannabis: Metabolism, Receptors, and Effects

Alcohol First-Pass Metabolism

Alcohol is primarily oxidized in the liver, but some metabolism occurs in the stomach via gastric alcohol dehydrogenase (ADH). Food in the stomach slows gastric emptying, allowing more time for this initial breakdown, which significantly lowers peak blood alcohol concentration (BAC) compared to drinking on an empty stomach.

The ADH-ALDH Metabolic Pathway

Alcohol is first converted into toxic acetaldehyde by alcohol dehydrogenase (ADH). Acetaldehyde is then rapidly converted into acetic acid by aldehyde dehydrogenase (ALDH). Genetic variations in ALDH (specifically an inactive form) lead to a buildup of acetaldehyde, causing the 'flushing response,' nausea, and tachycardia.

Disulfiram (Antabuse) Mechanism

A drug used to treat alcoholism that works by inhibiting ALDH. This causes a deliberate, aversive buildup of acetaldehyde if the user consumes even small amounts of alcohol, leading to intense physical discomfort.

Alcohol's Effect on Glutamate (Acute vs. Chronic)

Acute: Alcohol acts as an NMDA receptor antagonist, reducing glutamate release and causing memory loss. Chronic: The brain compensates by upregulating NMDA receptors. Withdrawal: Upon stopping, the excess receptors and a rebound increase in glutamate release cause CNS hyperexcitability, seizures, and potential cell death from excessive Ca 2+ influx.

Alcohol's Effect on GABA

Alcohol is a GABA-A receptor noncompetitive agonist, meaning it binds to a unique site to enhance Cl- conductance and hyperpolarize neurons. This widespread inhibition causes anxiolysis, sedation, and loss of motor coordination. Chronic use leads to a neuroadaptive decrease in GABA function (tolerance), contributing to withdrawal-induced tremors and anxiety.

Alcohol Reward Pathway (DA & Opioids)

Alcohol increases dopamine (DA) transmission in the mesolimbic tract (VTA to Nucleus Accumbens). It also stimulates the synthesis and release of endogenous opioids, which contribute to the drug's reinforcing and rewarding effects.

THC Pharmacokinetics (Inhaled vs. Oral)

Inhaled THC is rapidly absorbed by the lungs, reaching the brain quickly. Oral THC has a slower onset due to first-pass metabolism but a much longer duration (5+ hours). THC is highly fat-soluble and persists in fat tissue, meaning its elimination half-life is 20-30 hours and it can be detected in urine for weeks.

Retrograde Signaling of Endocannabinoids

Unlike most neurotransmitters, endocannabinoids (like Anandamide and 2-AG) act as retrograde messengers. They are released from the postsynaptic neuron and travel back to presynaptic CB1 receptors to inhibit the release of other neurotransmitters, such as glutamate or GABA.

Cannabinoid Reward Mechanism

THC stimulates DA release in the Nucleus Accumbens (NAc) by activating CB1 receptors on GABAergic nerve terminals in the VTA. This suppresses GABA's usual inhibition of DA neurons (disinhibition), allowing the DA cells to fire more frequently.

Opioid Cellular Mechanism (Inhibitory)

Opioids inhibit neurotransmission in two primary ways: (1) Presynaptic: They block Ca 2+ channels, reducing the release of neurotransmitters like glutamate; (2) Postsynaptic: They open K+ channels, hyperpolarizing the neuron and making it less likely to fire.

Opioids and the Spinothalamic vs. PAG Pathways

Opioids reduce pain through two 'top-down' and 'bottom-up' actions: they inhibit the spinothalamic tract (directly decreasing pain signals sent to the brain) and disinhibit the Periaqueductal Gray (PAG), which increases the brain's own descending inhibition of pain.

Methadone vs. Buprenorphine

Methadone is a long-acting mu-opioid full agonist that prevents withdrawal symptoms without causing significant euphoria. Buprenorphine is a partial agonist with a 'ceiling effect,' meaning it has a lower risk of respiratory depression and overdose compared to full agonists.

The Neurodevelopmental Model of Schizophrenia

Proposes that genetic or environmental assaults (e.g., prenatal viral infection) during early brain development create a vulnerability. During adolescence, further neurodevelopmental changes (like excessive pruning) lead to the emergence of symptoms. It suggests negative symptoms result from reduced frontal lobe function, while positive symptoms result from excessive mesolimbic DA activity.

Typical vs. Atypical Antipsychotics

Typical (Classic): Primarily D2 receptor antagonists; effective against positive symptoms but cause Extrapyramidal Symptoms (EPS) and Tardive Dyskinesia. Atypical (Second Generation): Target 5-HT 2 and D2 receptors; they have a lower risk of motor side effects but can cause significant weight gain and metabolic issues.

The Monoamine Hypothesis (and its Flaws)

The theory that depression is caused by low levels of monoamines (5-HT, NE, DA). The Flaw: While drugs increase monoamine levels within hours, clinical improvement takes weeks, suggesting that down-regulation of autoreceptors and changes in neuronal plasticity/connectivity are the actual drivers of recovery.

HPA Axis in Depression and Anxiety

In response to stress, the hypothalamus releases CRF, which eventually triggers the adrenal cortex to release cortisol. In healthy individuals, cortisol provides negative feedback to shut the system down. In depressed/anxious patients, this feedback loop is often impaired, leading to chronically high cortisol levels and hippocampal damage.

Ketamine's Antidepressant Mechanism

Unlike traditional SSRIs, Ketamine is an NMDA receptor antagonist. It works rapidly (within hours) by triggering a burst of glutamate that activates the mTOR signaling cascade, leading to increased neurogenesis and the rapid growth of new dendritic spines in the cortex.

Alcohol Dehydrogenase (ADH)

Enzyme that converts alcohol into acetaldehyde; present in both the liver and stomach.

Aldehyde Dehydrogenase (ALDH)

Enzyme that converts toxic acetaldehyde into acetic acid.

Disulfiram (Antabuse)

Drug that inhibits ALDH, causing a toxic buildup of acetaldehyde to deter drinking.

Acute Alcohol (Glutamate)

Acts as an NMDA receptor antagonist (reduces glutamate activity).

Chronic Alcohol (Glutamate)

Leads to the upregulation of NMDA receptors (the brain's attempt to compensate).

Alcohol Withdrawal

Massive glutamate release and NMDA hyperexcitability, leading to seizures and Ca 2+ toxicity.

Acute Alcohol (GABA)

GABA-A receptor agonist; increases chloride Cl- influx to hyperpolarize neurons.

Wernicke-Korsakoff Syndrome

Brain damage/memory loss caused by thiamine (Vitamin B1) deficiency due to chronic alcohol use.

CB1 Receptor

The primary cannabinoid receptor in the CNS; located on presynaptic terminals.

Retrograde Signaling

Endocannabinoids travel 'backward' from postsynaptic to presynaptic cells to inhibit neurotransmitter release.

THC Reward Mechanism

Inhibits GABA in the VTA, which 'disinhibits' dopamine neurons, increasing DA release in the NAc.

THC Metabolism

Highly fat-soluble; persists in fat stores for weeks, leading to a long elimination half-life.

Anandamide & 2-AG

The two primary endogenous cannabinoids (endocannabinoids).

Mu Opioid Receptor

The receptor primary responsible for analgesia (pain relief) and the high abuse potential of opioids.

Opioid Cellular Action

Inhibitory; closes Ca2+channels (presynaptic) and opens K+ channels (postsynaptic).

Periaqueductal Gray (PAG)

Brain area where opioids trigger descending pain inhibition by disinhibiting neurons.

Methadone

A long-acting full agonist used to treat opioid addiction by preventing withdrawal.

Buprenorphine

A partial agonist with a 'ceiling effect' on respiratory depression; safer than methadone.

Naloxone (Narcan)

An opioid antagonist used to rapidly reverse opioid overdose.

Positive Symptoms

Hallucinations and delusions; linked to excessive dopamine in the mesolimbic pathway.

Negative Symptoms

Social withdrawal and flat affect; linked to reduced dopamine/activity in the prefrontal cortex (hypofrontality).

Dopamine Hypothesis

Schizophrenia is caused by dysregulated dopamine (too much in limbic system, too little in PFC).

Typical Antipsychotics

D2 receptor antagonists; effective for positive symptoms but cause motor side effects (EPS).

Atypical Antipsychotics

Block D2 and 5-HT2 receptors; lower risk of motor side effects, better for negative symptoms.

Tardive Dyskinesia

A permanent motor disorder (involuntary movements) caused by long-term use of typical antipsychotics.

Antidepressant Time Lag

Theory that clinical benefit requires weeks of treatment to allow for autoreceptor downregulation and neuroplasticity.

HPA Axis

The stress system (Hypothalamus-Pituitary-Adrenal); chronically overactive in many depressed patients.

Cortisol

The 'stress hormone'; provides negative feedback to the HPA axis to shut down the stress response.

Ketamine

A rapid-acting antidepressant; acts as an NMDA antagonist and triggers the mTOR pathway for synaptogenesis.

Locus Coeruleus (LC)

The brain's main source of NE; hyperactivity here is associated with anxiety/panic.

Benzodiazepines

GABA A positive allosteric modulators; they enhance GABA's inhibitory effect to reduce anxiety.